131 related articles for article (PubMed ID: 34739855)
1. Trends and variations in the treatment of stage I-III small cell lung cancer from 2008 to 2019: A nationwide population-based study from the Netherlands.
Evers J; Hendriks LEL; De Jaeger K; Wijsman R; De Ruysscher D; Terhaard C; van der Sangen M; Siesling S; Struikmans H; Aarts MJ
Lung Cancer; 2021 Dec; 162():61-70. PubMed ID: 34739855
[TBL] [Abstract][Full Text] [Related]
2. Trends and variations in treatment of stage I-III non-small cell lung cancer from 2008 to 2018: A nationwide population-based study from the Netherlands.
Evers J; de Jaeger K; Hendriks LEL; van der Sangen M; Terhaard C; Siesling S; De Ruysscher D; Struikmans H; Aarts MJ
Lung Cancer; 2021 May; 155():103-113. PubMed ID: 33774382
[TBL] [Abstract][Full Text] [Related]
3. Treatment Variation of Sequential versus Concurrent Chemoradiotherapy in Stage III Non-Small Cell Lung Cancer Patients in the Netherlands and Belgium.
Walraven I; Damhuis RA; Ten Berge MG; Rosskamp M; van Eycken L; de Ruysscher D; Belderbos JSA
Clin Oncol (R Coll Radiol); 2017 Nov; 29(11):e177-e185. PubMed ID: 28780009
[TBL] [Abstract][Full Text] [Related]
4. [Concurrent chemoradiotherapy followed by consolidation chemotherapy and sequential chemoradiotherapy for stage III non-small cell lung cancer: comparison in 93 patients].
Sun WZ; Song LP; Zhang YB; Ai T; Lu JL; Ren J; Gao Y
Nan Fang Yi Ke Da Xue Xue Bao; 2012 Mar; 32(3):362-7. PubMed ID: 22445984
[TBL] [Abstract][Full Text] [Related]
5. Concurrent versus sequential chemoradiotherapy for unresectable locally advanced stage III non-small cell lung cancer: Retrospective analysis in a single United Kingdom cancer centre.
Spencer A; Williams J; Samuel R; Boon IS; Clarke K; Jain P
Cancer Treat Res Commun; 2021; 29():100460. PubMed ID: 34598059
[TBL] [Abstract][Full Text] [Related]
6. Development of symptomatic brain metastases after chemoradiotherapy for stage III non-small cell lung cancer: Does the type of chemotherapy regimen matter?
Hendriks LEL; Brouns -JWM; Amini M; Uyterlinde W; Wijsman R; Bussink J; Biesma B; Oei SB; Stigt JA; Bootsma GP; Belderbos JSA; De Ruysscher DKM; Van den Heuvel MM; Dingemans AC
Lung Cancer; 2016 Nov; 101():68-75. PubMed ID: 27794410
[TBL] [Abstract][Full Text] [Related]
7. Design and Rationale for a Phase II/III, Randomized, Double-Blind, Placebo-Controlled Study of Sugemalimab as Consolidation Therapy in Patients With Limited-Stage Small-Cell Lung Cancer Who Have Not Progressed Following Concurrent or Sequential Chemoradiotherapy: The SURPASS Study.
Zhao S; Chen K; Shi X; Sun J; Fang W; Huang Y; Zhang L
Clin Lung Cancer; 2023 Nov; 24(7):e254-e258. PubMed ID: 37442748
[TBL] [Abstract][Full Text] [Related]
8. The Dutch Lung Cancer Audit-Radiotherapy (DLCA-R): Real-World Data on Stage III Non-Small Cell Lung Cancer Patients Treated With Curative Chemoradiation.
Dieleman E; van der Woude L; van Os R; van Bockel L; Coremans I; van Es C; De Jaeger K; Knol HP; Kolff W; Koppe F; Pomp J; Reymen B; Schinagl D; Spoelstra F; Tissing-Tan C; van der Voort van Zyp N; van der Wel A; Wijsman R; Dielwart M; Wiegman E; Damhuis R; Belderbos J
Clin Lung Cancer; 2023 Mar; 24(2):130-136. PubMed ID: 36572596
[TBL] [Abstract][Full Text] [Related]
9. Toxicity and survival outcomes in older adults receiving concurrent or sequential chemoradiation for stage III non-small cell lung cancer in Alliance trials (Alliance A151812).
Maggiore RJ; Zahrieh D; McMurray RP; Feliciano JL; Samson P; Mohindra P; Chen H; Wong ML; Lafky JM; Jatoi A; Le-Rademacher JG
J Geriatr Oncol; 2021 May; 12(4):563-571. PubMed ID: 32950428
[TBL] [Abstract][Full Text] [Related]
10. Chemoradiation treatment patterns among United States Veteran Health Administration patients with unresectable stage III non-small cell lung cancer.
Hung A; Lee KM; Lynch JA; Li Y; Poonnen P; Efimova OV; Hintze BJ; Buckingham T; Yong C; Seal B; Kelley MJ; Reed SD
BMC Cancer; 2021 Jul; 21(1):824. PubMed ID: 34271861
[TBL] [Abstract][Full Text] [Related]
11. Predictors of chemoradiotherapy versus single modality therapy and overall survival among patients with unresectable, stage III non-small cell lung cancer.
Bobbili P; Ryan K; DerSarkissian M; Dua A; Yee C; Duh MS; Gomez JE
PLoS One; 2020; 15(3):e0230444. PubMed ID: 32187231
[TBL] [Abstract][Full Text] [Related]
12. Sequential chemoradiotherapy with accelerated hypofractionated radiotherapy compared to concurrent chemoradiotherapy with standard radiotherapy for locally advanced non-small cell lung cancer.
Zhu ZF; Ma HL; Fan M; Bao Y; Zhuang TT; Chen M; Jiang GL; Fu XL
Technol Cancer Res Treat; 2014 Jun; 13(3):269-75. PubMed ID: 24066952
[TBL] [Abstract][Full Text] [Related]
13. Role of sequential chemoradiotherapy in stage II and low-risk stage III-IV nasopharyngeal carcinoma in the era of intensity-modulated radiotherapy: A propensity score-matched analysis.
Xu C; Sun R; Tang LL; Chen L; Li WF; Mao YP; Zhou GQ; Guo R; Lin AH; Sun Y; Ma J; Hu WH
Oral Oncol; 2018 Mar; 78():37-45. PubMed ID: 29496056
[TBL] [Abstract][Full Text] [Related]
14. SOCCAR: A randomised phase II trial comparing sequential versus concurrent chemotherapy and radical hypofractionated radiotherapy in patients with inoperable stage III Non-Small Cell Lung Cancer and good performance status.
Maguire J; Khan I; McMenemin R; O'Rourke N; McNee S; Kelly V; Peedell C; Snee M
Eur J Cancer; 2014 Nov; 50(17):2939-49. PubMed ID: 25304298
[TBL] [Abstract][Full Text] [Related]
15. Patterns of care survey (PCS) in lung cancer: how well does current U.S. practice with chemotherapy in the non-metastatic setting follow the literature?
Langer CJ; Moughan J; Movsas B; Komaki R; Ettinger D; Owen J; Wilson JF
Lung Cancer; 2005 Apr; 48(1):93-102. PubMed ID: 15777975
[TBL] [Abstract][Full Text] [Related]
16. Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study.
Bradley JD; Paulus R; Komaki R; Masters G; Blumenschein G; Schild S; Bogart J; Hu C; Forster K; Magliocco A; Kavadi V; Garces YI; Narayan S; Iyengar P; Robinson C; Wynn RB; Koprowski C; Meng J; Beitler J; Gaur R; Curran W; Choy H
Lancet Oncol; 2015 Feb; 16(2):187-99. PubMed ID: 25601342
[TBL] [Abstract][Full Text] [Related]
17. Design and Rationale for a Phase III, Randomized, Placebo-controlled Trial of Durvalumab With or Without Tremelimumab After Concurrent Chemoradiotherapy for Patients With Limited-stage Small-cell Lung Cancer: The ADRIATIC Study.
Senan S; Okamoto I; Lee GW; Chen Y; Niho S; Mak G; Yao W; Shire N; Jiang H; Cho BC
Clin Lung Cancer; 2020 Mar; 21(2):e84-e88. PubMed ID: 31948903
[TBL] [Abstract][Full Text] [Related]
18. Rationale for concurrent chemoradiotherapy for patients with stage III non-small-cell lung cancer.
Conibear J;
Br J Cancer; 2020 Dec; 123(Suppl 1):10-17. PubMed ID: 33293671
[TBL] [Abstract][Full Text] [Related]
19. Sequential Versus Concurrent Chemoradiation Therapy by Surgical Margin Status in Resected Non-Small Cell Lung Cancer.
Verma V; Moreno AC; Haque W; Fang P; Lin SH
J Natl Compr Canc Netw; 2018 May; 16(5):508-516. PubMed ID: 29752325
[No Abstract] [Full Text] [Related]
20. [Induction chemotherapy followed by concomitant combined radiotherapy and chemotherapy in stage III non-small cell bronchial carcinoma].
Bouillet T; Morère JF; Mazeron JJ; Piperno-Neuman S; Boaziz C; Haddad E; Breau JL
Cancer Radiother; 1997; 1(2):121-31. PubMed ID: 9273182
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
